In addition, the neuroprotective effect of the administration of recombinant PARK7/DJ-1 was demonstrated in the rodent model of 6-hydroxydopamine (6-OHDA) and MG-132 treatment-induced PD [134]. This evidence concerns the gene PARK7 and Parkinson disease.